Olgu Sunumu
BibTex RIS Kaynak Göster
Yıl 2019, , 706 - 709, 16.12.2019
https://doi.org/10.31832/smj.596029

Öz

Kaynakça

  • 1. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging. J Am Soc Nephrol. 2006;17:2359–62. doi:10.1681/ASN.2006060601.2. Chien C-C, Wang H-Y, Wang J-J, Kan W-C, Chien T-W, Lin C-Y, et al. Risk of Acute Kidney Injury after Exposure to Gadolinium-Based Contrast in Patients with Renal Impairment. Ren Fail. 2011;33:758–64. doi:10.3109/0886022X.2011.599911.3. Takahashi EA, Kallmes DF, Mara KC, Harmsen WS, Misra S. Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up. Diagn Interv Radiol. 2018;24:378–84. doi:10.5152/dir.2018.18172.4. Schieda N, Maralani PJ, Hurrell C, Tsampalieros AK, Hiremath S. Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists. Can Assoc Radiol J. 2019. doi:10.1016/j.carj.2019.04.001.5. Perazella MA. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf. 2008;3:67–75. http://www.ncbi.nlm.nih.gov/pubmed/18690983. Accessed 21 Jul 2019.6. Fujisaki K, Ono-Fujisaki A, Kura-Nakamura N, Komune N, Hirakawa N, Tsuruya K, et al. Rapid deterioration of renal insufficiency after magnetic resonance imaging with gadolinium-based contrast agent. Clin Nephrol. 2011;75:251–4. doi:10.5414/cnp75251.7. Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron. 2012;120:c179–84. doi:10.1159/000339789.8. Tervahartiala P. Contrast media-induced renal tubular vacuolization after dehydration. A light and electron microscopic study in rats. Invest Radiol. 1992;27:114–8. http://www.ncbi.nlm.nih.gov/pubmed/1601601. Accessed 21 Jul 2019.9. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98:14K-20K. doi:10.1016/j.amjcard.2006.01.020.10. Akgun H, Gonlusen G, Cartwright J, Suki WN, Truong LD. Are gadolinium-based contrast media nephrotoxic? A renal biopsy study. Arch Pathol Lab Med. 2006;130:1354–7. doi:10.1043/1543-2165(2006)130[1354:AGCMNA]2.0.CO;2.11. Boyden TF, Gurm HS. Does gadolinium-based angiography protect against contrast-induced nephropathy?: a systematic review of the literature. Catheter Cardiovasc Interv. 2008;71:687–93. doi:10.1002/ccd.21459.12. Haustein J, Laniado M, Niendorf HP, Louton T, Beck W, Planitzer J, et al. Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology. 1993;186:855–60. doi:10.1148/radiology.186.3.8430199.13. Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging. 6:162–6. http://www.ncbi.nlm.nih.gov/pubmed/8851422. Accessed 21 Jul 2019.14. Sam AD, Morasch MD, Collins J, Song G, Chen R, Pereles FS. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg. 2003;38:313–8. http://www.ncbi.nlm.nih.gov/pubmed/12891113. Accessed 21 Jul 2019.

Gadolinuma Bağlı Akut Böbrek Hasarı: Bir Olgu Sunumu

Yıl 2019, , 706 - 709, 16.12.2019
https://doi.org/10.31832/smj.596029

Öz

Son zamanlarda, manyetik rezonans
görüntüleme (MRG) incelemeleri için kullanılan gadolinyum bazlı kontrast maddenin
(Gd-KM) akut böbrek hasarını (AKH) indüklediği bildirilmeye başlanmıştır.
Hiçbir risk faktörü olmayan, batın MRG sonrası AKH gelişen hastayı bildirmek
istedik. 

Kaynakça

  • 1. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging. J Am Soc Nephrol. 2006;17:2359–62. doi:10.1681/ASN.2006060601.2. Chien C-C, Wang H-Y, Wang J-J, Kan W-C, Chien T-W, Lin C-Y, et al. Risk of Acute Kidney Injury after Exposure to Gadolinium-Based Contrast in Patients with Renal Impairment. Ren Fail. 2011;33:758–64. doi:10.3109/0886022X.2011.599911.3. Takahashi EA, Kallmes DF, Mara KC, Harmsen WS, Misra S. Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up. Diagn Interv Radiol. 2018;24:378–84. doi:10.5152/dir.2018.18172.4. Schieda N, Maralani PJ, Hurrell C, Tsampalieros AK, Hiremath S. Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists. Can Assoc Radiol J. 2019. doi:10.1016/j.carj.2019.04.001.5. Perazella MA. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf. 2008;3:67–75. http://www.ncbi.nlm.nih.gov/pubmed/18690983. Accessed 21 Jul 2019.6. Fujisaki K, Ono-Fujisaki A, Kura-Nakamura N, Komune N, Hirakawa N, Tsuruya K, et al. Rapid deterioration of renal insufficiency after magnetic resonance imaging with gadolinium-based contrast agent. Clin Nephrol. 2011;75:251–4. doi:10.5414/cnp75251.7. Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron. 2012;120:c179–84. doi:10.1159/000339789.8. Tervahartiala P. Contrast media-induced renal tubular vacuolization after dehydration. A light and electron microscopic study in rats. Invest Radiol. 1992;27:114–8. http://www.ncbi.nlm.nih.gov/pubmed/1601601. Accessed 21 Jul 2019.9. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98:14K-20K. doi:10.1016/j.amjcard.2006.01.020.10. Akgun H, Gonlusen G, Cartwright J, Suki WN, Truong LD. Are gadolinium-based contrast media nephrotoxic? A renal biopsy study. Arch Pathol Lab Med. 2006;130:1354–7. doi:10.1043/1543-2165(2006)130[1354:AGCMNA]2.0.CO;2.11. Boyden TF, Gurm HS. Does gadolinium-based angiography protect against contrast-induced nephropathy?: a systematic review of the literature. Catheter Cardiovasc Interv. 2008;71:687–93. doi:10.1002/ccd.21459.12. Haustein J, Laniado M, Niendorf HP, Louton T, Beck W, Planitzer J, et al. Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology. 1993;186:855–60. doi:10.1148/radiology.186.3.8430199.13. Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging. 6:162–6. http://www.ncbi.nlm.nih.gov/pubmed/8851422. Accessed 21 Jul 2019.14. Sam AD, Morasch MD, Collins J, Song G, Chen R, Pereles FS. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg. 2003;38:313–8. http://www.ncbi.nlm.nih.gov/pubmed/12891113. Accessed 21 Jul 2019.
Toplam 1 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Sağlık Kurumları Yönetimi
Bölüm Makaleler
Yazarlar

Hamad Dheir

Serap Üngan Bu kişi benim

Ahmed Bilal Genç Bu kişi benim

Necattin Firat

Selcuk Yaylacı

Savaş Sipahi Bu kişi benim

Yayımlanma Tarihi 16 Aralık 2019
Gönderilme Tarihi 24 Temmuz 2019
Yayımlandığı Sayı Yıl 2019

Kaynak Göster

AMA Dheir H, Üngan S, Genç AB, Firat N, Yaylacı S, Sipahi S. Gadolinuma Bağlı Akut Böbrek Hasarı: Bir Olgu Sunumu. Sakarya Tıp Dergisi. Aralık 2019;9(4):706-709. doi:10.31832/smj.596029

30703

SMJ'de yayınlanan makaleler, Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı kapsamında lisanslanır